January 14, 2022 -- Castle Biosciences is touting the results of a study showing that the combined application of its DecisionDx technologies can analyze RNA and DNA from a single biopsy sample for patients with uveal melanoma.
The study, published in Ocular Oncology and Pathology, saw the use of the company's DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq panels.
Out of 105 tumors studied, DecisionDx-UMSeq achieved a positive percent agreement of 100% for detection of both single-nucleotide variants and insertions/deletions (INDELs), with a technical positive predictive value of 98.8% and 100%, respectively.
The company said combining the three technologies showed the highest accuracy for sample analysis.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.
Yes, Keep Me Current